Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury

• Published in: Journal of lipid research Vol. 58; no. 7; pp. 1439 - 1452
• Main Authors: Dupre, Tess V., Doll, Mark A., Shah, Parag P., Sharp, Cierra N., Siow, Deanna, Megyesi, Judit, Shayman, James, Bielawska, Alicja, Bielawski, Jacek, Beverly, Levi J., Hernandez-Corbacho, Maria, Clarke, Christopher J., Snider, Ashley J., Schnellmann, Rick G., Obeid, Lina M., Hannun, Yusuf A., Siskind, Leah J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2017; Journal of Lipid Research; The American Society for Biochemistry and Molecular Biology; Elsevier
• Subjects: Acute Kidney Injury - chemically induced; Acute Kidney Injury - metabolism; Acute Kidney Injury - physiopathology; Amitriptyline; Animals; Apoptosis; Cancer; Cell death; Cellular stress response; Ceramide; Ceramide glucosyltransferase; Ceramides - metabolism; Chemotherapy; Cisplatin; Cisplatin - adverse effects; Enzyme Inhibitors - pharmacology; Glucosyltransferases - antagonists & inhibitors; Glycosylation; inflammation; Kidney Cortex - blood supply; Kidney Cortex - drug effects; Kidney Cortex - metabolism; Kidneys; Male; Metabolism; Mice; Rats; Renal cortex; Reperfusion Injury - metabolism; Rodents; Sphingolipids; Sphingomyelin phosphodiesterase; apoptosis; ceramide; sphingolipids; inflammation
• ISSN: 0022-2275; 1539-7262
• DOI: 10.1194/jlr.M076745

Acute kidney injury (AKI), resulting from chemotherapeutic agents such as cisplatin, remains an obstacle in the treatment of cancer. Cisplatin-induced AKI involves apoptotic and necrotic cell death, pathways regulated by sphingolipids such as ceramide and glucosylceramide. Results from this study indicate that C57BL/6J mice treated with cisplatin had increased ceramide and hexosylceramide levels in the renal cortex 72 h following cisplatin treatment. Pretreatment of mice with inhibitors of acid sphingomyelinase and de novo ceramide synthesis (amitriptyline and myriocin, respectively) prevented accumulation of ceramides and hexosylceramide in the renal cortex and protected from cisplatin-induced AKI. To determine the role of ceramide metabolism to hexosylceramides in kidney injury, we treated mice with a potent and highly specific inhibitor of glucosylceramide synthase, the enzyme responsible for catalyzing the glycosylation of ceramides to form glucosylceramides. Inhibition of glucosylceramide synthase attenuated the accumulation of the hexosylceramides and exacerbated ceramide accumulation in the renal cortex following treatment of mice with cisplatin. Increasing ceramides and decreasing glucosylceramides in the renal cortex sensitized mice to cisplatin-induced AKI according to markers of kidney function, kidney injury, inflammation, cell stress, and apoptosis. Under conditions of high ceramide generation, data suggest that metabolism of ceramides to glucosylceramides buffers kidney ceramides and helps attenuate kidney injury.—Dupre, T. V., M. A. Doll, P. P. Shah, C. N. Sharp, D. Siow, J. Megyesi, J. Shayman, A. Bielawska, J. Bielawski, L. J. Beverly, M. Hernandez-Corbacho, C. J. Clarke, A. J. Snider, R. G. Schnellmann, L. M. Obeid, Y. A. Hannun, and L. J. Siskind. Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury. J. Lipid Res. 2017. 58: 1439–1452.